secwatch.observer — SEC 8-K summary
======================================

Issuer:     ASSEMBLY BIOSCIENCES, INC. (ASMB)
CIK:        0001426800
Form:       8-K
Filed at:   2025-02-20T23:59:59+00:00
Accession:  0000950170-25-024134
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Assembly Biosciences reports positive interim Phase 1a results for ABI-1179 in recurrent genital herpes
--------------------------------------------------------------------------------

- ABI-1179 had a half-life of ~4 days and high exposure across 50mg-300mg doses, supporting once-weekly oral dosing.
- ABI-1179 was well-tolerated with no serious adverse events and all treatment-emergent AEs mild and unrelated.
- Company plans to move directly into Phase 1b, running concurrently with Phase 1b of ABI-5366.
- Interim Phase 1b data for both ABI-1179 and ABI-5366 anticipated in fall 2025.
- ABI-1179 contributed by Gilead Sciences under the Assembly Bio-Gilead collaboration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1426800/000095017025024134/0000950170-25-024134-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1426800/000095017025024134/asmb-20250220.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-024134

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer